PROM1 and metastatic malignant neoplasm: Therefore, it remains important to better understand the characteristics of CSCs, CD133, and SOX2 for valuable therapeutic and prognostic targets in clinical practice to predict disease outcomes in advanced or metastatic cancer patients.